Description
CD14 is an acute phase glycoprotein that binds lipopolysaccharide endotoxins (LPS) from Gram-negative bacteria. It is primarily expressed on monocytes, macrophages, and neutrophils, and soluble forms can be secreted or shed from the cell surface. CD14 accepts LPS from its initial binding by LBP, and it can further transfer LPS to the TLR4/MD2 complex. LPS acctivation of TLR4 triggers inflammatory activation. CD14 also contributes to the response to TLR3 ligands, phosphoinositides, as well as the surfactant proteins SP-A and SP-D. MagCellect products are designed for the isolation of cells in a "liquid phase". MagCellect technology is based on the use of ferrofluids or magnetic nanoparticles that have no magnetic memory (superparamagnetic) and behave like colloidal particles. This feature allows the ferrofluids to remain in solution without the need for mixing and additionally allows for efficient diffusion kinetics during the binding reaction. The proprietary manufacturing technology of MagCellect Ferrofluids generates particles with higher ligand binding capacity per mass compared to many other larger diameter magnetic particles.
